Health Canada approved a marketing application for Atripla to treat HIV-1 infection. The once-daily fixed-dose combination tablet of GILD's Truvada emtricitabine/tenofovir and BMY's Sustiva efavirenz was approved in the U.S. in July 2006, and is currently under review in Europe. ...
